Delårsrapport Juli-September 2018

2018-11-08 | Regulatorisk

Mölndal, 8 november 2018 – Vicore Pharma Holding AB (publ) (ticker: VICO) publicerar delårsrapport för tredje kvartalet 2018.

Väsentliga händelser under tredje kvartalet

  • I juli meddelade Vicore att avtal om förvärv av INIM, som utvecklar en ny lokal behandling mot svåra ovanliga interstitiella lungsjukdomar, ingåtts. INIM ägdes till 85% av HealthCap VII L.P. som efter förvärvet blev största aktieägare i Vicore med 30,4% av aktierna
  • I augusti genomfördes en extra bolagsstämma i Vicore vilken beslutade om följande:
    – Förvärv av INIM genom en apportemission
    – Utdelning av huvuddelen av innehavet i I-Tech AB till aktieägarna i Vicore
    – Beslut om företrädesemission i Vicore
    – Beslut om incitamentsprogram till ledning och vissa styrelseledamöter
    – Inval av två nya styrelseledamöter i Vicore: Hans Schikan och Jacob Gunterberg
  • I augusti meddelade Vicore att Carl-Johan Dalsgaard utsetts till ny VD från den 1 september 2018
  • I september meddelade Vicore att det kliniska programmet VP01 (C21) utvidgas för att möjliggöra erhållandet av funktionella data och framgångsrikt kunna avancera C21 i klinisk utveckling
  • I september anställdes två nyckelpersoner i Vicore Pharma, Rohit Batta som CMO samt Göran Tornling som Senior Adviser

Väsentliga händelser efter periodens utgång

  • I oktober meddelade Vicore att den under september genomförda företrädesemissionen övertecknats med 33% och att 99,4% av teckningsrätterna utnyttjats
  • I oktober meddelade Göran Wessman att han av hälsoskäl på egen begäran utträder ur styrelsen och tar plats i Vicores valberedning
  • Styrelsen har den 8 november fattat beslut att verka för att Bolagets aktier skall upptas till handel på Nasdaq Stockholms huvudlista under 2019

Finansiell sammanställning

KSEK Jul-Sept 2018 Jul-Sept 2017 Jan-Sept 2018 Jan-Sept 2017 Helår 2017
Intäkter 785 929 2 467 2 680 3 674
Rörelseresultat -6 405 -1 685 -16 245 -6 512 -12 793
Resultat efter finansiella poster -6 667 -1 687 2 705 -6 573 -12 855
Resultat per aktie, SEK -0,27 -0,11 0,11 -0,41 -0,81
Eget kapital vid periodens slut 144 623 119 557 144 623 119 557 112 969
Kassaflödet för den löpande verksamheten 700 -1 718 8 375 -8 409 -7 703
Kassaflödet för investeringsverksamheten 14 845 -5 772 1 253 -13 665 -22 780
Kassaflödet för finansieringsverksamheten -1 438 0 -1 438 50 542 50 236
Likvida medel vid periodens slut 32 209 32 734 32 209 32 734 24 019

VD-ord

Bästa aktieägare,

Den 3 juli skapades grunden för det nya Vicore i och med förvärvet av INIM och det därtill kopplade beslutet att dela ut huvuddelen av aktierna i I-Tech till bolagets aktieägare. Vicore fick genom detta ett tydligt fokus på lungsjukdomar och en bredare portfölj inriktad mot Idiopatisk lungfibros (IPF) och andra ovanliga lungsjukdomar. Bolaget fick också en aktiv och erfaren stor ägare i HealthCap, en av Europas främsta investerare inom life science.

Vid den extra bolagsstämman den 13 augusti godkändes förvärvet och utdelningen av aktier. På stämman valdes också två nya styrelseledamöter, Hans Schikan med lång erfarenhet från biotechindustrin och Jacob Gunterberg från HealthCap, in i bolagets styrelse. Vidare fattades beslut om den företrädesemission som framgångsrikt slutfördes den 3 oktober, efter kvartalets utgång. Teckningsrätterna utnyttjades till   99,4%, emissionen   övertecknades med 33 procent och tillförde bolaget 82,4 MSEK före emissionskostnader.

Det var med dessa beslut tagna som jag utnämndes till VD i Vicore från 1 september. Jag hade själv varit med och drivit denna affär då jag såg en stor potential i att föra samman Vicore och INIM för att kraftsamla inom lungsjukdomar. Vicores Pharmas data kring C21 och den biologiska verkningsmekanism C21 adresserar kunde kompletteras på ett utmärkt sätt av INIMs utvecklingsprojekt inom interstitiella lungsjukdomar.

Efter en strategisk översyn tog vi i början av september beslutet att utvidga Vicores kliniska program VP01 för C21 så att den planerade fas IIa-studien med C21 för behandling av IPF även ska kunna inkludera data avseende lungfunktion, d.v.s. data både på säkerhet och effekt. Vår översyn inkluderade resultaten från den tidigare genomförda längre prekliniska säkerhetsstudien som visade att vi har möjlighet att öka exponeringen för att fastställa högre doser av C21 i människa innan den mest optimala doseringen väljs ut för den kliniska IPF-studien. Vi planerar att initiera det utökade programmet under januari 2019 för att sedan kunna starta fas IIa-studien sex månader senare.

I   september   förstärktes   Vicores Pharmas organisation   med två nyckelpersoner som båda besitter den form av specialistkompetens och erfarenhet vi behöver för att bygga värde inom vårt kärnområde, svåra, ovanliga lungsjukdomar. Det är Dr. Rohit Batta som har lång erfarenhet både som läkare och ledare av medicinska och kliniska utvecklingsteam inom ”rare diseases”, senast som Senior Director of Cell and Gene Therapy på GlaxoSmithKline (GSK), och Dr. Göran Tornling, med nära fyrtio års erfarenhet som specialistläkare i lungmedicin och som tidigare varit Executive Director, Clinical Science and Strategy (Respiratory) på AstraZeneca och där varit ansvarig för design av studier inom IPF. Båda ingår i Vicores ledningsgrupp och de kommer att vara mycket värdefulla när vi nu bygger ett medicinskt team av världsklass för det fortsatta kliniska utvecklingsarbetet.

När jag tog mig an VD-rollen i Vicore såg jag goda möjligheter att skapa ett internationellt ledande bolag inom svåra och ovanliga lungsjukdomar. Nu, efter två månader, är jag ännu mera övertygad om detta.

Carl-Johan Dalsgaard

For ytterligare information, vänligen kontakta:

Dr. Carl-Johan Dalsgaard, CEO: +46 (0)70 975 98 63, carl-johan.dalsgaard@vicorepharma.com

Hans Jeppsson, CFO: + 46 (0)70 553 14 65, hans.jeppsson@vicorepharma.com

Denna information är sådan information som Vicore Pharma Holding AB är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning. Informationen lämnades, genom ovanstående kontaktpersons försorg, för offentliggörande den 8 november 2018 kl. 08.30 CET

Vicorepharma

On vicorepharma.com, we use so-called cookies to analyze how our website is used in order to optimize and improve it. You choose yourself whether you want to consent to our use of cookies.

Vicorepharma is responsible for placing cookies on the website and for the processing of your personal data collected by them. For more information about our processing of your personal data, see our privacy policy

Cookie policy

Your consent applies to the following domain: vicorepharma.com
The cookie policy was last updated: 2023-01-24

Privacy Policy

Show the cookies used on our website

Necessary cookies is needed in order for the website's basic functions to work correctly and for us to be able to save your choice of cookies.

  • cookies_set

    Purpose: Saves the visitor’s choice of cookies.
    Issued by: mk cookie master
    Lifespan: 1 year

    Domain: vicorepharma.com

  • selected_cookies

    Purpose: Saves the visitor’s choice of cookies.
    Issued by: mk cookie master
    Lifespan: 1 year

    Domain: vicorepharma.com

Marketing cookies is used to track visitors on the website. The intention is to show ads that are relevant and engaging to the individual user and thus be more valuable to publishers and third-party advertisers.

  • AMP_TOKEN

    Purpose: Contains a token that can be used to retrieve a unique user ID.
    Issued by: AMP
    Lifespan: 1 year

    Domain: vicorepharma.com

  • _fbp

    Purpose: Used to store and track visits across websites.
    Issued by: Facebook
    Lifespan: 3 months

    Domain: vicorepharma.com

  • _gac_

    Purpose: Used to store and track audience reach.
    Issued by: Google Ads
    Lifespan: 90 days

    Domain: vicorepharma.com

  • _lfa

    Purpose: Used to store and track audience reach.
    Issued by: Leadfeeder
    Lifespan: 2 years

    Domain: vicorepharma.com

  • _lfa_test_cookie_stored

    Purpose: Used to test if _lfa was stored.
    Issued by: Leadfeeder
    Lifespan: 1 day

    Domain: vicorepharma.com

Statistical cookies helps the website owners to understand how visitors interact with the website by collecting and report this information.

  • _clck

    Purpose: Used to store a unique user ID.
    Issued by: Microsoft Clarity
    Lifespan: 1 year

    Domain: vicorepharma.com

  • _clsk

    Purpose: Used to store and combine pageviews by a user into a single session recording.
    Issued by: Microsoft Clarity
    Lifespan: 1 day

    Domain: vicorepharma.com

  • _ga

    Purpose: Used to understand how visitors’ navigate around the website.
    Issued by: Google Analytics
    Lifespan: 2 years

    Domain: vicorepharma.com

  • _gat

    Purpose: Used to throttle request rate. If Google Analytics is deployed via Google Tag Manager, this cookie will be named _dc_gtm_.
    Issued by: Google Analytics
    Lifespan: 1 minute

    Domain: vicorepharma.com

  • _gid

    Purpose: Used to understand how visitors’ navigate around the website.
    Issued by: Google Analytics
    Lifespan: 1 day

    Domain: vicorepharma.com

  • _hjAbsoluteSessionInProgress

    Purpose: Used to store unique visits.
    Issued by: Hotjar
    Lifespan: 30 minutes

    Domain: vicorepharma.com

  • _hjFirstSeen

    Purpose: Used to identify a new visitors’ first session.
    Issued by: Hotjar
    Lifespan: Session

    Domain: vicorepharma.com

  • _hjid

    Purpose: Used to store a unique user ID.
    Issued by: Hotjar
    Lifespan: 1 year

    Domain: vicorepharma.com

  • _hjIncludedInPageviewSample

    Purpose: Used to check if the visitor is included in the data sample defined by the site’s daily pageview limit.
    Issued by: Hotjar
    Lifespan: 30 minutes

    Domain: vicorepharma.com

  • _hjIncludedInSessionSample

    Purpose: Used to check if the visitor is included in the data sample defined by the site’s daily session limit.
    Issued by: Hotjar
    Lifespan: 30 minutes

    Domain: vicorepharma.com

  • _hjSessionUser{site_id}

    Purpose: Used to store a unique user ID.
    Issued by: Hotjar
    Lifespan: 1 year

    Domain: vicorepharma.com

  • _hjSession{site_id}

    Purpose: A cookie that holds the current session data.
    Issued by: Hotjar
    Lifespan: 30 minutes

    Domain: vicorepharma.com

  • _hjTLDTest

    Purpose: Used to check if cookies can be loaded on the site and is removed shortly afterward.
    Issued by: Hotjar
    Lifespan: Session

    Domain: vicorepharma.com

What are cookies?

A cookie is a small text file that is placed on your device (computer/mobile/tablet that has access to the internet) by the website you visit – if you give your consent to this. The cookie can, for example, recognize you as a user when you visit our website and make it possible to remember important information that makes your visit more comfortable and provides an improved user experience. Cookies are so-called passive files that cannot spread dangerous software or viruses on your mobile device or computer.

 

There are two types of cookies, permanent cookies and session cookies. At vicorepharma.com we use both permanent cookies and session cookies. Permanent cookies are saved as a file on the computer for a certain time until the server that placed them, or you as a visitor choose to delete them. Session cookies are temporarily stored when you as a visitor are on the website and disappear when you close your browser.

 

Cookies can also be divided into first-party cookies and third-party cookies. First-party cookies are placed by the website you are visiting, while third-party cookies are placed by another website. At vicorepharma.com, we use both first-party cookies and third-party cookies.

 

How to avoid cookies

When you visit our website, you can refuse all or certain types of cookies. You can also withdraw or change your consent at any time by clicking here.

 

You can also block cookies by changing the settings in your browser. Then your browser will automatically refuse cookies or inform you when a website requests to store cookies.

 

After your visit, you can review and delete the permanent cookies that have been stored in your browser. In the list below, you will see the name of the cookies vicorepharma.com saves so that you can easily identify them.

 

Here you will find more information about how to manage cookies in your browser:

 

Cookies used by third parties

On vicorepharma.com there may be content that is embedded from YouTube. YouTube places cookies in your browser when you visit youtube.com or when you click on embedded content from YouTube on our website. vicorepharma cannot control these cookies or the personal data and information that may be collected. vicorepharma does not use the targeted marketing services offered by YouTube. As a user, you therefore need to check YouTube’s website for further information on how they manage cookies, what information they collect and how you can delete any third-party cookies.

Necessary cookies is needed in order for the website's basic functions to work correctly and for us to be able to save your choice of cookies.

  • cookies_set

    Purpose: Saves the visitor’s choice of cookies.
    Issued by: mk cookie master
    Lifespan: 1 year

    Domain: vicorepharma.com

  • selected_cookies

    Purpose: Saves the visitor’s choice of cookies.
    Issued by: mk cookie master
    Lifespan: 1 year

    Domain: vicorepharma.com

Marketing cookies is used to track visitors on the website. The intention is to show ads that are relevant and engaging to the individual user and thus be more valuable to publishers and third-party advertisers.

  • AMP_TOKEN

    Purpose: Contains a token that can be used to retrieve a unique user ID.
    Issued by: AMP
    Lifespan: 1 year

    Domain: vicorepharma.com

  • _fbp

    Purpose: Used to store and track visits across websites.
    Issued by: Facebook
    Lifespan: 3 months

    Domain: vicorepharma.com

  • _gac_

    Purpose: Used to store and track audience reach.
    Issued by: Google Ads
    Lifespan: 90 days

    Domain: vicorepharma.com

  • _lfa

    Purpose: Used to store and track audience reach.
    Issued by: Leadfeeder
    Lifespan: 2 years

    Domain: vicorepharma.com

  • _lfa_test_cookie_stored

    Purpose: Used to test if _lfa was stored.
    Issued by: Leadfeeder
    Lifespan: 1 day

    Domain: vicorepharma.com

Statistical cookies helps the website owners to understand how visitors interact with the website by collecting and report this information.

  • _clck

    Purpose: Used to store a unique user ID.
    Issued by: Microsoft Clarity
    Lifespan: 1 year

    Domain: vicorepharma.com

  • _clsk

    Purpose: Used to store and combine pageviews by a user into a single session recording.
    Issued by: Microsoft Clarity
    Lifespan: 1 day

    Domain: vicorepharma.com

  • _ga

    Purpose: Used to understand how visitors’ navigate around the website.
    Issued by: Google Analytics
    Lifespan: 2 years

    Domain: vicorepharma.com

  • _gat

    Purpose: Used to throttle request rate. If Google Analytics is deployed via Google Tag Manager, this cookie will be named _dc_gtm_.
    Issued by: Google Analytics
    Lifespan: 1 minute

    Domain: vicorepharma.com

  • _gid

    Purpose: Used to understand how visitors’ navigate around the website.
    Issued by: Google Analytics
    Lifespan: 1 day

    Domain: vicorepharma.com

  • _hjAbsoluteSessionInProgress

    Purpose: Used to store unique visits.
    Issued by: Hotjar
    Lifespan: 30 minutes

    Domain: vicorepharma.com

  • _hjFirstSeen

    Purpose: Used to identify a new visitors’ first session.
    Issued by: Hotjar
    Lifespan: Session

    Domain: vicorepharma.com

  • _hjid

    Purpose: Used to store a unique user ID.
    Issued by: Hotjar
    Lifespan: 1 year

    Domain: vicorepharma.com

  • _hjIncludedInPageviewSample

    Purpose: Used to check if the visitor is included in the data sample defined by the site’s daily pageview limit.
    Issued by: Hotjar
    Lifespan: 30 minutes

    Domain: vicorepharma.com

  • _hjIncludedInSessionSample

    Purpose: Used to check if the visitor is included in the data sample defined by the site’s daily session limit.
    Issued by: Hotjar
    Lifespan: 30 minutes

    Domain: vicorepharma.com

  • _hjSessionUser{site_id}

    Purpose: Used to store a unique user ID.
    Issued by: Hotjar
    Lifespan: 1 year

    Domain: vicorepharma.com

  • _hjSession{site_id}

    Purpose: A cookie that holds the current session data.
    Issued by: Hotjar
    Lifespan: 30 minutes

    Domain: vicorepharma.com

  • _hjTLDTest

    Purpose: Used to check if cookies can be loaded on the site and is removed shortly afterward.
    Issued by: Hotjar
    Lifespan: Session

    Domain: vicorepharma.com

General

Vicore Pharma Holding AB (“Vicore”) shall only process personal data in accordance with applicable data protection law and high industry standards.

 

Personal data.

Vicore processes personal data provided to us;
(i) by you in the day-to-day communications, or

(ii) in connection with entering into or performing an agreement or business arrangement with you, or
(iii) by a third party allowed by law or your consent.

The personal data may consist of contact and identification details and other information relevant to the situation.

 

Purpose.

Vicore process personal data for the purpose of communicating with you and to perform, manage and comply with agreements between us as well as rights and obligations which are allowed by law or applicable regulation.

 

Legal grounds.

The legal grounds for processing personal data is either;
(i) your consent which shall be considered provided when you either voluntary submit the personal data or enter into an agreement with us, or
(ii) a legitimate interest allowed under law.

 

Security

Vicore shall use adequate technical and organisational security measures to protect the personal data from loss and to safeguard against access from unauthorised persons.

Transfers of personal data may only occur;
(i) to third parties who perform services on Vicore behalf and who may only process personal data in accordance with our instructions, and may not use personal data for their own purposes; and
(ii) outside the EU/EEA only in accordance with applicable data protection laws and subject to the EU Commission’s standard contractual clauses, and
(iii) as otherwise permitted by law or your consent.

Duration.

The duration we process personal data is limited to what is reasonable for the purpose of the processing, unless otherwise required or permitted by law.

 

Rights

Vicore is the controller of the personal data processing, meaning that we are responsible for that the personal data is processed correctly and in accordance with applicable data protection laws.

Unless prevented by applicable law, regulation or agreement data subjects have the right to;
(i) know what personal data we process about them,
(ii) request that we rectify or erase inaccurate or incomplete personal data
(iii) object to specific processing of personal data, and
(iv) receive the personal data provided by them and have the personal data transferred to another party responsible for data processing.

All communications with Vicore regarding how we process personal data or exercise of any of your rights can be sent by e-mail to info@vicorepharma.com or by post to the address above.

Reports and complaints can also be directed to Datainspektionen who is the supervisory authority for our processing of personal data.